Revenue segments as reported by the company.

Medical Devices

Specialty Pharmaceuticals

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Research and development

Royalty expense

Amortization expense

Intangible asset impairment charges

Contingent consideration net expense (benefit)

Restructuring net charges (credits)

Litigation-related net charges (credits)

Gain on disposal of businesses and assets

Goodwill impairment charges

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Boston Scientific

Boston Scientific Corp. engages in the development, manufacture and marketing of medical devices that are used in interventional medical specialties. It operates through the following segments: Rhythm and Neuro, Cardiovascular and MedSurg. The Rhythm and Neuro segment develops implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities. The Cardiovascular segment consists of technologies for diagnosing and treating coronary artery disease and other cardiovascular disorders including structural heart conditions. The MedSurg segment focuses on Endoscopy, which provides devices to diagnose and treat a broad range of gastrointestinal and pulmonary conditions with innovative and invasive technologies. The company was founded by John E. Abele and Pete Michael Nicholas on June 29, 1979, and is headquartered in Marlborough, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Boston Scientific reports solid Q4 performance and eyes global growth

Boston Scientific's Q4 performance was solid, with growth across regions and business units.
Challenges include potential sales growth hurdles in Q1 2023 and headwinds from tough comps and market adjustments.
Opportunities lie in continued momentum in key business units, successful product launches, and global growth prospects.
The company remains focused on sustaining growth, expanding margins, and delivering double-digit adjusted EPS growth.

Boston Scientific surpasses Q1 expectations, eyes growth through Farapulse

Boston Scientific's Q1 '23 earnings call showcased strong performance, with exceeding revenue expectations and solid organic sales growth. The company's strategic focus on high-growth M&A, resolving supply constraints for Farapulse, and capital allocation priorities position it well for future growth. Challenges include potential earnings dilutive deals and addressing free cash flow conversion challenges.

Boston Scientific surpasses Q2 expectations, eyes margin expansion and innovation

Boston Scientific delivered a strong Q2 '23 performance, exceeding expectations with robust sales growth and improved adjusted EPS, driven by strong performance across key regions and business segments.
While facing challenges such as inflation impact and market dynamics, the company remains focused on opportunities for margin expansion, product innovation, and strategic acquisitions to drive future growth.
With a positive outlook for the coronary business, upcoming product launches, and a commitment to operational excellence, Boston Scientific aims to maintain its competitive edge and capitalize on market opportunities.
Anticipated results from trials, market potential for new products, and a focus on sustainable growth strategies position Boston Scientific for continued success and market leadership in the healthcare sector.

Boston Scientific surpasses Q3 expectations, eyes growth opportunities ahead

Boston Scientific's Q3 2023 results exceeded expectations, with strong performance across regions and business units.
The company raised full-year guidance, expecting organic revenue growth of approximately 11% and adjusted EPS range of $1.99 to $2.02.
Challenges in the Neuromodulation business and cost impacts are being addressed for future improvement.
Opportunities lie in acquisitions, FDA approvals, and strategic commercial initiatives for growth and margin expansion.

Boston Scientific (BSX) exceeds Q4 expectations, eyes growth opportunities

Boston Scientific (BSX) reported impressive Q4 2023 results, exceeding sales and EPS guidance.
The company showcased strong regional growth, highlighted key products, and outlined solid 2024 outlook.
While facing challenges like delayed product launches and market disruptions, BSX remains focused on growth opportunities.
Strategic acquisitions and margin improvement initiatives position Boston Scientific for continued success in the future.

Boston Scientific beats Q1 expectations, eyes growth in key markets

Boston Scientific delivered strong Q1 results, exceeding expectations and showcasing growth across key regions and business units.
While facing challenges like inventory charges, the company is focused on leveraging opportunities in expanding product indications and enhancing capabilities.
With raised full-year guidance and a focus on innovation and market expansion, Boston Scientific is poised for continued growth and success in 2024.

Boston Scientific (BSX) reports stellar Q2 results and eyes sustained growth

Boston Scientific's Q2 2024 performance exceeded expectations, showcasing strong financial results and regional sales growth across key markets.
The company's strategic strengths lie in diversified business units, innovative products like FARAPULSE, and strategic acquisitions like Silk Road Medical.
While challenges exist in adoption metrics and margin expansion, BSX's focus on reinvestment and growth opportunities position it well for sustained success.

Boston Scientific surpasses Q3 expectations, eyes growth opportunities in Asia

Boston Scientific's Q3 performance exceeded expectations, driven by strong sales growth and increased adjusted EPS.
The company's focus on innovation and strategic investments in key business units like Cardiology and Neuromodulation bode well for future growth.
Despite challenges in China and the need to deliver on growth targets, Boston Scientific remains confident in its ability to sustain top-tier financial performance.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Boston Scientific Corp. engages in the development, manufacture, and marketing of medical devices that are used in interventional medical procedures. It operates through the MedSurg and Cardiovascular segments. The MedSurg segment includes Endoscopy, Urology, and Neuromodulation. The Cardiovascular segment consists of Cardiology and Peripheral Interventions. The company was founded by John E. Abele and Pete Michael Nicholas on June 29, 1979 and is headquartered in Marlborough, MA.

Becton, Dickinson and Co.

Becton Dickinson & Co. Deposit Repr 1/20th Cum Conv Pfd Registered Series A

Medtronic

Royal Philips

The Food and Drug Administration likely won't pull medical devices coated in chemotherapy drug paclitaxel from the market, an analyst said Thursday. But it could require additional studies.

Why The FDA Likely Won't Pull These Medical Devices From The Market

Boston Scientific Corporation (NYSE: BSX) delivered a first-quarter miss  in April and adjusted its 2019 guidance.

BMO Adds Boston Scientific To Top Picks, Sees Catalysts Ahead

Wedbush Adds Boston Scientific To Top Picks, Sees Catalysts Ahead

Amphastar Pharma

Kforce

Life Storage

TerraForm Power

Village Super Market

Zillow

TerraForm Power, Zillow Group and Boston Scientific are just some of the top stocks to buy as May turns into June.
The post 7 Stocks to Buy for June appeared first on InvestorPlace.

7 Stocks to Buy for June

Johnson & Johnson

Merck

Pfizer

U.S. equities are mostly higher in post-holiday trading on Tuesday, as investors are looking for stocks to buy.

4 Drug and Health Stocks Pushing Higher  

Hewlett Packard

Centene

The stock charts of HPE, CNC and BSX are going to get the new trading week started on the verge of major moves.
The post 3 Big Stock Charts for Tuesday: Centene, Boston Scientific and Hewlett Packard Enterprise appeared first on InvestorPlace.

3 Big Stock Charts for Tuesday: Centene, Boston Scientific and Hewlett Packard Enterprise

Boston Scientific (BSX) reported earnings 30 days ago. What's next for the stock?

Why Is Boston Scientific (BSX) Up 2.3% Since Last Earnings Report?

We have been managing a position in Boston Scientific (NYSE:BSX) since early mid-February of this year. BSX is a medical device company that manufactures coronary stent systems, cancer treatment catheter systems, Parkinson’s deep brain stimulation systems and more.

Collect Income on This Medical Device Company in May

ABIOMED

Edwards Lifesciences

HCA Healthcare

Illumina

The health care sector should benefit from a shift towards more defensive names in 2019.

Top 5 Health Care Stocks of 2018 by Performance

Boston Scientific recently reported its Q1 results, which were in line with our estimates.

How Did Boston Scientific Fare In Q1, And What To Expect From Full Year 2019?

The medical device maker posted solid revenue and earnings growth -- but not enough to make Wall Street happy.

Boston Scientific Disappoints With Its Q1 Earnings Results

Boston Scientific Corporation (BSX) CEO Michael Mahoney on Q1 2019 Results - Earnings Call Transcript

Boston Scientific (BSX) is investing in new technologies and the global markets, which in turn, aids the uptick in sales across its most geographies in Q1.

Boston Scientific (BSX) Misses Q1 Earnings, Tightens EPS View

Shares of Boston Scientific Corp. dropped 1.2% in premarket trade Wednesday, after the medical technology company missed first-quarter profit and revenue expectations.

Boston Scientific's stock falls after profit, sales come up shy of expectations

Boston Scientific is expected to publish its Q1 2019 results on April 24. This note details Trefis’ forecasts for Boston Scientific, as well as some of the key trends we will be watching when the company reports earnings.

What To Expect From Boston Scientific's Q1

Boston Scientific will likely cut its 2019 outlook, an analyst said Monday after the Food and Drug Administration dealt the medical device company a pair of setbacks in March and April.

Why This High-Growth Medtech Stock Might Cut Its 2019 Outlook

We are optimistic about Boston Scientific's (BSX) IC business that will help maintain its impressive global growth trend in Q1 owing to an innovative portfolio and strong commercial teams.

Can Boston Scientific's (BSX) Steady Growth Aid Q1 Earnings?

Shares of Boston Scientific slumped 4.3%.

The FDA cracks down on surgical mesh: Boston Scientific

Boston Scientific Corporation traded lower Tuesday after the U.S.Food and Drug Administration ordered the company to stop selling its surgical mesh products used for transvaginal repair of pelvic organ prolapse due to safety concerns.

FDA Determines Boston Scientific Hasn't Showed Reasonable Assurance Of Safety, Effectiveness For Surgical Meshes

Boston Scientific toppled Tuesday after the Food and Drug Administration ordered it and a Danish company to stop selling a medical device that repairs pelvic organ prolapse in women.

Boston Scientific Dives On FDA Order To Stop Selling Medical Device

The Food and Drug Administration orders Boston Scientific and Coloplast to stop selling surgical mesh used for some pelvic operations.

FDA orders Boston Scientific, Coloplast to stop selling surgical mesh

Boston Scientific’s Endoscopy business refers to the company’s devices to diagnose and treat a broad range of gastrointestinal and pulmonary conditions.

How Important Is Endoscopy Business For Boston Scientific's Stock?

Boston Scientific Corporation provides specialized products and services for the medical industry.

Boston Scientific: New-Found Profitability After A Decade Of Volatility

A Food and Drug Administration warning about possible dangers from balloons and stents coated with the drug paclitaxel is bad news for Boston Scientific Corporation's Eluvia stent, but Bank of America Merrill Lynch is still recommending the stock.

BofA Lowers Boston Scientific Revenue Estimates On FDA Warning, But Keeps Buy Rating

Boston Scientific (BSX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

News for Boston Scientific Stock (BSX)